Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000018634
JPRN-UMIN000018634
Completed
未知

Exploration of Predictive factors for response to Enzaltamide in bone metastasis of Prostate cancer - EPEP study

Department of Urology, Juntendo University Graduate School of Medicine0 sites100 target enrollmentAugust 10, 2015
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsBone metastasis of prostate cancer

Overview

Phase
未知
Intervention
Not specified
Conditions
Bone metastasis of prostate cancer
Sponsor
Department of Urology, Juntendo University Graduate School of Medicine
Enrollment
100
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 10, 2015
End Date
December 31, 2020
Last Updated
2 years ago
Study Type
Observational
Sex
Male

Investigators

Sponsor
Department of Urology, Juntendo University Graduate School of Medicine

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •1\. Patients treated by chemotherapy 2\. Patients judged to be inappropriate to perform this study by investigator

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Research to identify factors that predict response to enzalutamide using biopsy tissues from castration-resistant prostate cancer.castration resistant prostate cancerprostate cancer, castration-resistant, enzalutamideD064129
JPRN-jRCTs051180140Akamatsu Shusuke340
Recruiting
Not Applicable
The study of predictive factors for the effect of Salmeterol/Fluticasone combination(SFC) on the patients with obstructive pulmonary dysfunction.obstructive pulmonary dysfunction
JPRN-UMIN000010276Kagoshima university pulmonary medicine60
Recruiting
Phase 4
Predictive factors and magnitude of response to omalizumab and mepolizumab in allergic and eosinophilic severe asthma: PREDICTUMAB, an open-label, controlled, randomized multinational pragmatic trial.
2024-516783-29-00Cliniques Universitaires Saint-Luc340
Active, not recruiting
Phase 1
Predictive factors of response to omalizumab and mepolizumab in asthma.Adult patients (18-90 years old) with severe asthma and eligible for both XOLAIR and NUCALA therapies, and agreeing on participating (signature of a written informed consent).Therapeutic area: Diseases [C] - Immune System Diseases [C20]
EUCTR2017-002473-19-FRCliniques Universitaires Saint-Luc364
Completed
Not Applicable
The contributing factors to the responsiveness of inhaled corticosteroids in patients with untreated asthmaasthma
JPRN-UMIN000021486agoya City University Dept of Respiratory Medicine, Allergy and Clinical Immunology13